First-Line Pharmacotherapies and Survival among Patients Diagnosed with Non-Resectable NSCLC: A Real-Life Setting Study with Gender Prospective
SIMPLE SUMMARY: Women and men have a different biomolecular profile that could impact drug utilization and survival in non-small cell lung cancer (NSCLC) patients. The aim of the study was to describe first-line pharmacotherapy and overall survival in non-resectable (nr)NSCLC patients by gender. Abo...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8657179/ https://www.ncbi.nlm.nih.gov/pubmed/34885238 http://dx.doi.org/10.3390/cancers13236129 |
_version_ | 1784612451301457920 |
---|---|
author | Spini, Andrea Gini, Rosa Rosellini, Pietro Singier, Allison Bellan, Cristiana Pascucci, Alessandra Leoncini, Lorenzo Mathieu, Clément Martellucci, Ignazio Furiesi, Folco Giorgi, Silvano Donnini, Sandra Roberto, Giuseppe Ziche, Marina Salvo, Francesco |
author_facet | Spini, Andrea Gini, Rosa Rosellini, Pietro Singier, Allison Bellan, Cristiana Pascucci, Alessandra Leoncini, Lorenzo Mathieu, Clément Martellucci, Ignazio Furiesi, Folco Giorgi, Silvano Donnini, Sandra Roberto, Giuseppe Ziche, Marina Salvo, Francesco |
author_sort | Spini, Andrea |
collection | PubMed |
description | SIMPLE SUMMARY: Women and men have a different biomolecular profile that could impact drug utilization and survival in non-small cell lung cancer (NSCLC) patients. The aim of the study was to describe first-line pharmacotherapy and overall survival in non-resectable (nr)NSCLC patients by gender. About 4400 incident cases of nrNSCLC were included. We reported a different use of target therapies on the basis of the known biomolecular profile between the two sexes. The survival improved in the last decade, and women and men also showed different survival if diagnosed with a squamous or non-squamous nrNSCLC. ABSTRACT: (1) Purpose: To describe first-line pharmacotherapy and overall survival in non-resectable non-small cell lung cancer (nrNSCLC) patients by gender. (2) Methods: Incident cases of nrNSCLC recorded between 2009 and 2019 (cohort entry) in the pathology registry of the regional administrative healthcare database of Tuscany were identified. Records of antineoplastic therapies delivered up to 4 months following cohort entry were classified as chemotherapy, target therapies, immunotherapies, and undefined monoclonal antibodies. First-line treatment and survival of patients receiving drug treatment was described. Analyses were stratified according to histology, gender, and cohort entry year. (3) Results: 4393 incident cases of nrNSCLC were included. Women with non-squamous-NSCLC received target-therapy more frequently than men (14.9% vs. 6.5%). Immunotherapy incidence of use varied between 3.8% (2017) and 9.1% (2019). The 2-year survival rate increased over time: for non-squamous-NSCLC, it was 22.3% (2009–2011) and 30.6% (2018–2019), while for squamous-NSCLC, it was 13.5% and 22.5%, respectively. After multivariate analysis, a low reduction in mortality risk in 2018–2019 vs. 2009–2011 was found (non-squamous: HR: 0.95 CI95%: 0.92–0.98; squamous: HR: 0.94 CI95%: 0.90–0.98). Among non-squamous NSCLC, median survival was longer in women than in men (389 vs. 276 days). (4) Conclusion: In light of sex-related biomolecular differences, among non-squamous NSCLC, women received target-therapy more frequently than men. Survival seemed to slightly improve over the study period for both histologies, despite a poor reduction in mortality risk was still observed. |
format | Online Article Text |
id | pubmed-8657179 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-86571792021-12-10 First-Line Pharmacotherapies and Survival among Patients Diagnosed with Non-Resectable NSCLC: A Real-Life Setting Study with Gender Prospective Spini, Andrea Gini, Rosa Rosellini, Pietro Singier, Allison Bellan, Cristiana Pascucci, Alessandra Leoncini, Lorenzo Mathieu, Clément Martellucci, Ignazio Furiesi, Folco Giorgi, Silvano Donnini, Sandra Roberto, Giuseppe Ziche, Marina Salvo, Francesco Cancers (Basel) Article SIMPLE SUMMARY: Women and men have a different biomolecular profile that could impact drug utilization and survival in non-small cell lung cancer (NSCLC) patients. The aim of the study was to describe first-line pharmacotherapy and overall survival in non-resectable (nr)NSCLC patients by gender. About 4400 incident cases of nrNSCLC were included. We reported a different use of target therapies on the basis of the known biomolecular profile between the two sexes. The survival improved in the last decade, and women and men also showed different survival if diagnosed with a squamous or non-squamous nrNSCLC. ABSTRACT: (1) Purpose: To describe first-line pharmacotherapy and overall survival in non-resectable non-small cell lung cancer (nrNSCLC) patients by gender. (2) Methods: Incident cases of nrNSCLC recorded between 2009 and 2019 (cohort entry) in the pathology registry of the regional administrative healthcare database of Tuscany were identified. Records of antineoplastic therapies delivered up to 4 months following cohort entry were classified as chemotherapy, target therapies, immunotherapies, and undefined monoclonal antibodies. First-line treatment and survival of patients receiving drug treatment was described. Analyses were stratified according to histology, gender, and cohort entry year. (3) Results: 4393 incident cases of nrNSCLC were included. Women with non-squamous-NSCLC received target-therapy more frequently than men (14.9% vs. 6.5%). Immunotherapy incidence of use varied between 3.8% (2017) and 9.1% (2019). The 2-year survival rate increased over time: for non-squamous-NSCLC, it was 22.3% (2009–2011) and 30.6% (2018–2019), while for squamous-NSCLC, it was 13.5% and 22.5%, respectively. After multivariate analysis, a low reduction in mortality risk in 2018–2019 vs. 2009–2011 was found (non-squamous: HR: 0.95 CI95%: 0.92–0.98; squamous: HR: 0.94 CI95%: 0.90–0.98). Among non-squamous NSCLC, median survival was longer in women than in men (389 vs. 276 days). (4) Conclusion: In light of sex-related biomolecular differences, among non-squamous NSCLC, women received target-therapy more frequently than men. Survival seemed to slightly improve over the study period for both histologies, despite a poor reduction in mortality risk was still observed. MDPI 2021-12-05 /pmc/articles/PMC8657179/ /pubmed/34885238 http://dx.doi.org/10.3390/cancers13236129 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Spini, Andrea Gini, Rosa Rosellini, Pietro Singier, Allison Bellan, Cristiana Pascucci, Alessandra Leoncini, Lorenzo Mathieu, Clément Martellucci, Ignazio Furiesi, Folco Giorgi, Silvano Donnini, Sandra Roberto, Giuseppe Ziche, Marina Salvo, Francesco First-Line Pharmacotherapies and Survival among Patients Diagnosed with Non-Resectable NSCLC: A Real-Life Setting Study with Gender Prospective |
title | First-Line Pharmacotherapies and Survival among Patients Diagnosed with Non-Resectable NSCLC: A Real-Life Setting Study with Gender Prospective |
title_full | First-Line Pharmacotherapies and Survival among Patients Diagnosed with Non-Resectable NSCLC: A Real-Life Setting Study with Gender Prospective |
title_fullStr | First-Line Pharmacotherapies and Survival among Patients Diagnosed with Non-Resectable NSCLC: A Real-Life Setting Study with Gender Prospective |
title_full_unstemmed | First-Line Pharmacotherapies and Survival among Patients Diagnosed with Non-Resectable NSCLC: A Real-Life Setting Study with Gender Prospective |
title_short | First-Line Pharmacotherapies and Survival among Patients Diagnosed with Non-Resectable NSCLC: A Real-Life Setting Study with Gender Prospective |
title_sort | first-line pharmacotherapies and survival among patients diagnosed with non-resectable nsclc: a real-life setting study with gender prospective |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8657179/ https://www.ncbi.nlm.nih.gov/pubmed/34885238 http://dx.doi.org/10.3390/cancers13236129 |
work_keys_str_mv | AT spiniandrea firstlinepharmacotherapiesandsurvivalamongpatientsdiagnosedwithnonresectablensclcareallifesettingstudywithgenderprospective AT ginirosa firstlinepharmacotherapiesandsurvivalamongpatientsdiagnosedwithnonresectablensclcareallifesettingstudywithgenderprospective AT rosellinipietro firstlinepharmacotherapiesandsurvivalamongpatientsdiagnosedwithnonresectablensclcareallifesettingstudywithgenderprospective AT singierallison firstlinepharmacotherapiesandsurvivalamongpatientsdiagnosedwithnonresectablensclcareallifesettingstudywithgenderprospective AT bellancristiana firstlinepharmacotherapiesandsurvivalamongpatientsdiagnosedwithnonresectablensclcareallifesettingstudywithgenderprospective AT pascuccialessandra firstlinepharmacotherapiesandsurvivalamongpatientsdiagnosedwithnonresectablensclcareallifesettingstudywithgenderprospective AT leoncinilorenzo firstlinepharmacotherapiesandsurvivalamongpatientsdiagnosedwithnonresectablensclcareallifesettingstudywithgenderprospective AT mathieuclement firstlinepharmacotherapiesandsurvivalamongpatientsdiagnosedwithnonresectablensclcareallifesettingstudywithgenderprospective AT martellucciignazio firstlinepharmacotherapiesandsurvivalamongpatientsdiagnosedwithnonresectablensclcareallifesettingstudywithgenderprospective AT furiesifolco firstlinepharmacotherapiesandsurvivalamongpatientsdiagnosedwithnonresectablensclcareallifesettingstudywithgenderprospective AT giorgisilvano firstlinepharmacotherapiesandsurvivalamongpatientsdiagnosedwithnonresectablensclcareallifesettingstudywithgenderprospective AT donninisandra firstlinepharmacotherapiesandsurvivalamongpatientsdiagnosedwithnonresectablensclcareallifesettingstudywithgenderprospective AT robertogiuseppe firstlinepharmacotherapiesandsurvivalamongpatientsdiagnosedwithnonresectablensclcareallifesettingstudywithgenderprospective AT zichemarina firstlinepharmacotherapiesandsurvivalamongpatientsdiagnosedwithnonresectablensclcareallifesettingstudywithgenderprospective AT salvofrancesco firstlinepharmacotherapiesandsurvivalamongpatientsdiagnosedwithnonresectablensclcareallifesettingstudywithgenderprospective |